Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Naga P. Chalasani, Quentin M. Anstee, Kris V. Kowdley, Jacob George, Zachary D.

Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1‐PRKACA fusion

Rondell P. Graham, Carolin Lackner, Luigi Terracciano, Yessica González‐Cantú, Joseph J. Maleszewski, Patricia T. Greipp, Sanford M. Simon, Michael S. Torbenson – 9 December 2017 – Fibrolamellar carcinomas are characterized by activation of protein kinase A, a kinase composed of catalytic and regulatory subunits. PRKACA encodes a catalytic subunit of protein kinase A, and almost all fibrolamellar carcinomas have a heterozygous 400‐kb deletion that leads to the fusion of DNAJB1 and PRKACA.

Survival of children after liver transplantation for hepatocellular carcinoma

Ulrich Baumann, René Adam, Christophe Duvoux, Rafael Mikolajczyk, Vincent Karam, Lorenzo D'Antiga, Christophe Chardot, Ahmet Coker, Michele Colledan, Bo‐Goran Ericzon, Pål Dag Line, Nedim Hadzic, Helena Isoniemi, Jürgen L. Klempnauer, Raymond Reding, Patrick J. McKiernan, Valérie McLin, Andreas Paul, Mauro Salizzoni, Emanuel San Bento Furtado, Stefan Schneeberger, André Karch, for the European Liver and Intestine Transplant Association – 9 December 2017 – Hepatocellular carcinoma (HCC) in childhood differs from adult HCC because it is often associated with inherited liver disease.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Naga P. Chalasani, Quentin M. Anstee, Kris V. Kowdley, Jacob George, Zachary D.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

Zobair M. Younossi, Rohit Loomba, Quentin M. Anstee, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Zachary D. Goodman, Naga P. Chalasani, Kris V.

Transplanting hepatitis C virus–positive livers into hepatitis C virus–negative patients with preemptive antiviral treatment: A modeling study

Jagpreet Chhatwal, Sumeyye Samur, Emily D. Bethea, Turgay Ayer, Fasiha Kanwal, Chin Hur, Mark S. Roberts, Norah Terrault, Raymond T. Chung – 9 December 2017 – Under current guidelines, hepatitis C virus (HCV)‐positive livers are not transplanted into HCV‐negative recipients because of adverse posttransplant outcomes associated with allograft HCV infection.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

Zobair M. Younossi, Rohit Loomba, Quentin M. Anstee, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Zachary D. Goodman, Naga P. Chalasani, Kris V.

Subscribe to